Home › NDC Lookup › Ingredients › Epinephrine › 00093-5986-27
Epinephrine 1 mg/mL Injection — NDC 00093-5986-27 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Epinephrine 1 mg/mL Injection — NDC 0093-5986-27 (Billing 00093-5986-27)

by Teva Pharmaceuticals USA, Inc. · 2 CONTAINER in 1 CARTON / 1 SYRINGE in 1 CONTAINER / .3 mL in 1 SYRINGE

This is a package of Epinephrine 1 mg/mL Injection from Teva Pharmaceuticals USA, Inc., marketed since Dec 2021 and currently FDA-listed; retail pharmacies pay about $133.60 per unit (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 00093-5986-27
🏷️ FDA NDC (as labeled) 0093-5986-27 billing pads the labeler segment with a zero
This package
Contains.3 mL in 1 syringe Cost per ea$133.60 NADAC Per package$267.19 / 2 syringes Pack sizes2 compare ↓
Also priced by: Medicaid pays $433.21/unit · Part D plans $136.87/unit — full pricing hub ↓
Main listing for product 0093-5986 · Also comes in: 1280 syringes 0093-5986-99
On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0093-5986-27 alone.

Record
FDA NDC Directory package listing · Drug for further processing
Code segments
0093 labeler · 5986 product · 27 package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 0093598627 2
Medicaid fills, this package
187,077 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026
⚠️
Other active recalls for Epinephrine (different manufacturers) — 2 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class III · May 14, 2026 — Failed Impurities/Degradations Specifications (Fresenius Kabi USA, LLC) · FDA recall D-0581-2026
Class II · Apr 1, 2026 — Lack of Assurance of Sterility (International Medication Systems Ltd.) · FDA recall D-0483-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0093-5986-27
Product NDC 0093-5986
11-digit billing NDC 00093598627
NCPDP billing unit EA — each (per item)
SPL Set ID 425b32b4-a2ac-4987-a1c7-71be5d33f515
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2021-12-07
Dosage form INJECTION
Substance EPINEPHRINE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 3890004000D540
GPI class EPINEPHrine
GCN Seq No 016879
GCN 19862
HICL code 002050
Ingredient (HICL) Epinephrine
HIC1 code J
Therapeutic class — broad (HIC1) Autonomic Nervous System
HIC2 code J5
Therapeutic class — intermediate (HIC2) Adrenergics
HIC3 code J5F
Therapeutic class — specific (HIC3) Anaphylaxis Therapy Agents
AHFS code 12:12.12.00
AHFS class Alpha- And Beta-Adrenergic Agonists
FDB label name EPINEPHRINE 0.3 MG AUTO-INJECT
FDB brand name Epinephrine
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 016879
  • GCN: 19862
  • GPI-14 (Medi-Span): 3890004000D540
  • HICL (First Databank): 002050
  • AHFS class code: 12:12.12.00
Why two NDCs? The FDA registers this code as 0093-5986-27 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00093-5986-27. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name EPINEPHRINE 0.3 MG AUTO-INJECT Ingredient Epinephrine
📗 Our plain-language guide HelloPharmacist
  • Its main use is emergency treatment of severe allergic reactions, including anaphylaxis from stings, foods or drugs. Some injections are also used for low blood pressure in septic...
  • Yes. Epinephrine is emergency first aid, not a replacement for medical care. Call for help right after using it so you can be monitored and treated further if needed.
  • Do I still need to go to the hospital after using it?
  • Into the outer middle part of the thigh, through clothing if needed. Never inject into a vein, the buttock, or fingers, hands or feet. For young children, hold the leg firmly so th...
📖 Read our full Epinephrine guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $133.597 $267.19 / 2 syringes
Medicaid paysCMS SDUD · 12 mo $433.21 $866.41 / 2 syringes
Medicare drug plans payPart D · Q2 2026 $136.87 $273.74 / 2 syringes
Medicare Part B allowsASP · J0165 $0.234 / J0165 unit —
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $141.565 $132.829
▼ Down 3% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Billing & reimbursement

FDA NDC (as labeled)0093-5986-27
11-digit billing NDC00093-5986-27
Format4-4-2 as registered → padded to 5-4-2 for billing (zero added to the labeler segment)
HCPCS J-codeJ0165
DescriptorINJECTION, EPINEPHRINE, NOT OTHERWISE SPECIFIED, 0.1 MG
Billing units / pkg3 units
How the units are derivedThis package is 2 EA; the HCPCS unit is 0.1 MG, so one package = 3 billing units.
Medicare Part B spend (2026 (Q1))$165 · 152 claims · $1.08 per claim (all NDCs under J0165)
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00093-5986-27 You're viewing this Main listing 2 CONTAINER in 1 CARTON / 1 SYRINGE in 1 CONTAINER / .3 mL in 1 SYRINGE $133.60 / ea $267.19 2018-11-27 — Active
00093-5986-99 0093-5986-99 1280 SYRINGE in 1 BOX / 1 mL in 1 SYRINGE — — — — Active

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 2 container in 1 carton / 1 syringe in 1 container / .3 ml in 1 syringe.
What NDC number is used to bill for this package of Epinephrine 1 mg/mL Injection?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Adrenalin 1 mg/mL 42023-0159-25 Par 25 vials $7.796 AP Availability likely save 94%
Epinephrine 1 mg/mLthis 00093-5986-27 Teva 1 syringe $133.597 — Availability likely —
Epinephrine .3 mg/.3mL 49502-0102-02 Viatris 1 syringe $141.276 AB Availability likely +6%
Epipen .3 mg/.3mL 49502-0500-02 Viatris 1 syringe $292.748 AB FDA listed +119%
Epinephrine .3 mg/.3mL 50090-4543-00 A-S 1 ml — AB FDA listed —
Epinephrine .3 mg/.3mL 67296-1946-02 Redpharm 1 syringe — AB FDA listed —
Epinephrine 0.3 Adults .3 mg/.3mL 70385-2019-01 Sina 1 syringe — AB FDA listed —
Epinephrine .3 mg/.3mL 70518-2283-00 REMEDYREPACK 1 syringe — AB FDA listed —
Epinephrine .3 mg/.3mL 71872-7135-01 Medical 1 syringe — AB FDA listed —
Epinephrine .3 mg/.3mL 76420-0188-02 Asclemed 2 syringes — AB FDA listed —
Epipen .3 mg/.3mL 76420-0584-02 Asclemed 1 syringe — AB FDA listed —
Epinephrine .3 mg/.3mL 85766-0091-02 Sportpharm 1 syringe — AB FDA listed —
Epinephrine 1 mg/mL 71872-7117-01 Medical 1 ampule — AP FDA listed —
Adrenalin 1 mg/mL 71872-7223-01 Medical 1 vial — AP FDA listed —
Adrenalin 1 mg/mL 84549-0159-25 ProPharma 1 ml — AP FDA listed —
Epinephrine 1 mg/mL 63323-0698-30 Fresenius 1 vial — — FDA listed —
Epinephrine 1 mg/mL 00404-9857-01 Henry 1 ampule — AP FDA listed —
Epinephrine 1 mg/mL 54288-0600-01 BPI 1 vial — AP FDA listed —
epinephrine 1 mg/mL 68083-0633-01 Gland 1 vial — AP FDA listed —
epinephrine 1 mg/mL 68462-0760-10 GLENMARK 1 vial — AP FDA listed —
Epinephrine 1 mg/mL 70518-4156-00 REMEDYREPACK 25 vials — AP FDA listed —
Epinephrine 1 mg/mL 70518-4274-00 REMEDYREPACK 25 vials — AP FDA listed —
epinephrine 1 mg/mL 43066-0801-02 Baxter 1 vial — — FDA listed —
Epinephrine 1 mg/mL 63323-0696-25 Fresenius 25 vials — AP FDA listed —
Epinephrine 1 mg/mL 50090-3039-00 A-S 25 ampules — AP Discontinued —
Epinephrine 1 mg/mL 80830-1659-02 Amneal 25 vials — AP FDA listed —
epinephrine 1 mg/mL 68462-0933-10 GLENMARK 10 ampules — AP FDA listed —
epinephrine 1 mg/mL 00517-1171-10 American 10 ampules — — FDA listed —
Epinephrine 1 mg/mL 43835-0026-02 Novo 1 syringe — — FDA listed —
Epinephrine 1 mg/mL 61434-0040-01 Catalent 1280 syringes — — FDA listed —
Epinephrine 1 mg/mL 54288-0120-01 BPI 1 vial — AP FDA listed —
Epinephrine 1 mg/mL 71872-7360-01 Medical 1 vial — AP FDA listed —
Epinephrine 1 mg/mL 72572-0238-01 CIVICA, 1 vial — — FDA listed —
epinephrine 1 mg/mL 00662-1695-60 Hospira, 12 cellos — — FDA listed —
Adrenalin 1 mg/mL 42023-0168-01 Par 1 vial — AP FDA listed —
Epinephrine 1 mg/mL 54288-0117-10 BPI 10 syringes — AP FDA listed —
Epinephrine 1 mg/mL 54288-0119-10 BPI 10 vials — AP FDA listed —
epinephrine 1 mg/mL 68462-0761-30 GLENMARK 1 vial — AP FDA listed —
Epinephrine 1 mg/mL 00517-3030-01 American 1 vial — AP FDA listed —
Epinephrine 1 mg/mL 76329-9060-00 International 1 vial — AP FDA listed —
Epinephrine 1 mg/mL 84549-0103-10 ProPharma 1 ml — AP FDA listed —
epinephrine 1 mg/mL 43066-0803-25 Baxter 25 vials — — FDA listed —
epinephrine 1 mg/mL 70121-1660-02 Amneal 1 vial — AP FDA listed —
Adrenalin Vials 1 mg/mL 70385-2024-02 Sina 2 vials — AP FDA listed —
Epinephrine 1 mg/mL 00143-9476-25 Hikma 25 ampules — AP FDA listed —
Epinephrine 1 mg/mL 54288-0103-10 BPI 10 ampules — AP FDA listed —
epinephrine 1 mg/mL 68083-0591-10 Gland 10 ampules — AP FDA listed —
epinephrine 1 mg/mL 68083-0685-01 Gland 1 vial — AP FDA listed —
Epinephrine 1 mg/mL 72572-0235-25 CIVICA, 25 vials — AP Discontinued —
Adrenalin 1 mg/mL 70518-1342-00 REMEDYREPACK 25 vials — AP Discontinued —
Epinephrine 1 mg/mL 51662-1706-01 HF 1 ml — AP FDA listed —
Epinephrine 1 mg/mL 51662-1708-01 HF 1 ml — AP FDA listed —
epinephrine 1 mg/mL 68083-0699-10 Gland 10 vials — AP FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2021
On the market since
Dec 2021
📍
2026
Currently FDA-listed
5 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Epinephrine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII QTT17582CB
    A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
  • UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
  • UNII 4VON5FNS3C
    Sodium metabisulfite is a preservative derived from sulfur compounds. It prevents microbial growth and oxidation in medicines, helping extend shelf life and maintain product stability.
  • UNII DIA7C37AOW
    Sodium tartrate dihydrate is a salt derived from tartaric acid, a naturally occurring compound found in grapes. It acts as a buffer and pH regulator in medicines, helping maintain the proper acidity level for stability and effectiveness.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

5 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerTeva Pharmaceuticals USA, Inc.
Labeler code00093
First marketedDec 2021
Product typeDrug For Further Processing
Portfolio504 products on file

More NDCs from Teva Pharmaceuticals USA, Inc. labeler code 00093

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
187.1K
Units reimbursed last 4 qtrs
118.9K
Gross reimbursed last 4 qtrs
$51.52M
Avg / prescription
$275.38
Avg / unit
$433.21
Latest quarter Q1 2026
39.2KRx
Medicaid pays / ea
$433.21
gross reimbursed
vs
NADAC / ea
$133.60
acquisition cost
=
Spread
+$299.61
+224% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
40% FFS 60% MCO
Fee-for-service · 74,304 Rx Managed care · 112,773 Rx
State Medicaid map
Alaska: 323 units · 44.1 per 100k residents AK Maine: 1,942 units · 139 per 100k residents ME Washington: 4,855 units · 62.1 per 100k residents WA Idaho: 390 units · 19.9 per 100k residents ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 217 units · 3.8 per 100k residents MN Wisconsin: no data reported WI Michigan: 5,144 units · 51.3 per 100k residents MI New York: 20,749 units · 106 per 100k residents NY Vermont: no data reported VT New Hampshire: 903 units · 64.4 per 100k residents NH Oregon: 2,965 units · 70.0 per 100k residents OR Nevada: 1,330 units · 41.6 per 100k residents NV Wyoming: 194 units · 33.2 per 100k residents WY South Dakota: 175 units · 19.0 per 100k residents SD Iowa: 214 units · 6.7 per 100k residents IA Illinois: 4,240 units · 33.8 per 100k residents IL Indiana: 2,485 units · 36.2 per 100k residents IN Ohio: 177 units · 1.5 per 100k residents OH Pennsylvania: 1,062 units · 8.2 per 100k residents PA New Jersey: 2,481 units · 26.7 per 100k residents NJ Massachusetts: 4,005 units · 57.2 per 100k residents MA California: 13,399 units · 34.4 per 100k residents CA Utah: 785 units · 23.0 per 100k residents UT Colorado: 758 units · 12.9 per 100k residents CO Nebraska: no data reported NE Missouri: 112 units · 1.8 per 100k residents MO Kentucky: 2,823 units · 62.4 per 100k residents KY West Virginia: 122 units · 6.9 per 100k residents WV Virginia: 6,140 units · 70.4 per 100k residents VA Maryland: 2,634 units · 42.6 per 100k residents MD Connecticut: 390 units · 10.8 per 100k residents CT Rhode Island: 419 units · 38.3 per 100k residents RI Arizona: 148 units · 2.0 per 100k residents AZ New Mexico: 2,145 units · 101 per 100k residents NM Kansas: 643 units · 21.9 per 100k residents KS Arkansas: 79 units · 2.6 per 100k residents AR Tennessee: 2,595 units · 36.4 per 100k residents TN North Carolina: 9,269 units · 85.5 per 100k residents NC South Carolina: 368 units · 6.8 per 100k residents SC Delaware: no data reported DE Oklahoma: 1,929 units · 47.6 per 100k residents OK Louisiana: 3,627 units · 79.3 per 100k residents LA Mississippi: no data reported MS Alabama: 1,643 units · 32.2 per 100k residents AL Georgia: 5,944 units · 53.9 per 100k residents GA D.C.: 494 units · 72.8 per 100k residents DC Hawaii: 448 units · 31.2 per 100k residents HI Texas: 4,358 units · 14.3 per 100k residents TX Florida: 3,577 units · 15.8 per 100k residents FL
Units reimbursed · per 100k residents
1.5139
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Maine 139 /100k
2 New York 106 /100k
3 New Mexico 101 /100k
4 North Carolina 85.5 /100k
5 Louisiana 79.3 /100k
6 D.C. 72.8 /100k
7 Virginia 70.4 /100k
8 Oregon 70.0 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 syringe this page00093-5986-27 187,077 Rx · $51,516,450
1280 syringes00093-5986-99 No Medicaid data
Drug total (last 4 qtrs): 187,077 Rx · 118,919 units · $51,516,450 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Epinephrine (matched by generic name) — the program that covers self-administered drugs. 4 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Epinephrine. CMS lists 6 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$29.01M
Claims incl. refills
120.5K
Beneficiaries
110.8K
Spend / beneficiary
$261.75
Spend / claim
$240.69
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Teva Pharmaceuticals USA, Inc. supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk ✓ Available
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Teva Pharmaceuticals USA, Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 1280 syringes (00093-5986-99). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Teva Pharmaceuticals USA, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Does this product have a billing J-code?
Yes — this NDC cross-references HCPCS code J0165 for medical-claim billing (typically used when a product is administered in a clinical setting rather than dispensed at a retail pharmacy). See the Billing section on this page.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00093-5985-27 · Teva 00093-6031-82 · Teva →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.